<DOC>
	<DOCNO>NCT00154440</DOCNO>
	<brief_summary>The first objective study confirm result complete remission low-grade gastric MALT lymphoma stage IE &amp; II1E H. pylorus eradication large number patient ( HELYX Part I ) . If response antibiotic therapy , role radiotherapy course gastric MALT lymphoma investigate consecutive therapeutic option patient H. pylori- negative , ( 11 ; 18 ) -positive failure candidate eradication therapy . Furthermore , method radiation , radiation dose investigate standardized . HELYX PART II therefore randomize equivalent study compare standard dose 36Gy vs. reduce dose 25.2Gy locoregional . Additional molecular genetic analysis perform try understand pathogenetic mechanism lymphomagenesis .</brief_summary>
	<brief_title>Helicobacter – Lymphoma – Radiation Part I : Eradication , Part II : Radiation</brief_title>
	<detailed_description>Experimental data extend knowledge mere association gastric MALT lymphoma infection Helicobacter pylorus . If summarise report date result treatment gastric low-grade MALT lymphoma early clinical stage ( EI ) H. pylori eradication find complete remission figure 77 % 200 patient . As therapy le side effect radiation , surgery chemotherapy stomach-conserving treatment , eradication H. pylorus patient low-grade gastric MALT lymphoma stage IE &amp; II1E treatment choice within clinical trial since long-term result available thus far . Besides , pretreatment patient selection careful follow-up endoscopy , biopsy clinical stag include endoscopic ultrasonography necessary . However , five ten year-follow-up necessary definitive value Helicobacter pylorus eradication establish . Furthermore , since patient respond therapy research pathogenetic mechanism lymphomagenesis inevitable . Approximately 20 % patient antigen-positive , primary gastric low-grade MALT lymphoma stage I respond eradication therapy . Hence , consecutive salvage therapy surgery much need . The aim second part study establish radiation therapy salvage therapy . Furthermore , effect reduce radiation dose ( 25.2Gy ) compare standard dose ( 36Gy ) investigate aim non-inferiority dos .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>histologically diagnose , primary gastric lowgrade Bcell MALT lymphoma stage IE II1E , Helicobacter pyloripositive ( histology , urease test , serology ) inclusion HELYX part I histologically diagnose , primary gastric lowgrade Bcell MALT lymphoma stage IE II1E , Helicobacter pylorinegative ( histology , urease test , serology ) inclusion HELYX part II patient achieve study end point HELYX I : partial remission change 12 month successful antibiotic therapy inclusion HELYX part II , age &gt; 18 &lt; 75 year KarnofskyIndex &gt; 60 % sufficient liver function , define bilirubin &lt; 34µmol/l sufficient renal function , define creatinine &lt; 133µmol/l write informed consent complete clinical tumor stag primary gastric lowgrade MALT lymphoma , stag &gt; II1E gastric highgrade lymphoma lymphoma entity stomach e.g . lymphoblastic lymphoma Burkitt ’ lymphoma age &lt; 18 &gt; 75 year KarnofskyIndex &lt; 60 % insufficient liver renal function ( see ) HIVinfection pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>primary gastric MALT lymphoma</keyword>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>eradication therapy</keyword>
	<keyword>radiation</keyword>
	<keyword>marginal zone B-cell lymphoma</keyword>
	<keyword>Mucosa-associated Lymphoid Tissue</keyword>
	<keyword>B-cell Non-Hodgkin 's Lymphoma stomach</keyword>
	<keyword>primary gastric lymphoma</keyword>
</DOC>